Our corporate information is that we will be the Leading Light for Life to deliver world class state of the art drugs that offer individuals from round the world a healthy life. Through our knowledge in these drug discovery programs and subsequent clinical trials, we had fostered the notion that we must provide novel solutions for enhancing the supplier Letrozole health of well-defined populations of patients experiencing several cancers. We call it the precision medicine approach. Precision medicine has become cure option for many cancers. In July 2011, the US Food and Drug Administration released the draft guidance for in vitro partner diagnostic products. In August 2011, the FDA permitted ZelborafTM, a kinase inhibitor, for the treatment of patients with unresectable or metastatic melanoma whose tumors express a gene mutation named BRAF V600E together with a diagnostic test to detect such mutation in patients Cellular differentiation melanoma cells. The FDA also permitted Xalkoriw, a kinase inhibitor, for treating patients with locally advanced level or metastatic non-small cell lung cancer who express the abnormal anaplastic lymphoma kinase gene together with a diagnostic test to detect such abnormal gene Astellas has three sites for oncology drug discovery, specifically Astellas Pharma Inc. Tsukuba Research Center at Tsukuba, Ibaraki, Asia, OSI Pharmaceuticals, LLC at Farmingdale, Nyc, Us, and Agensys, Inc. at Santa Monica, CA, USA. The three research websites follow perfection medicine in an approach based on the research system and research strategy of each site. Tsukuba Research Center Evacetrapib LY2484595 centers on the development of small molecules that inhibit the function of molecules which are crucial for the survival or growth of tumor cells as a result of either genetic or epigenetic changes to the drug goal molecules themselves or in the presence of specific genetic or epigenetic contexts. So that you can create drugs to well defined patient populations, Tsukuba Research Center is placing significant emphasis on efforts to recognize and verify novel molecular targets based on in house research and external partnerships. It should be noted that these target discovery efforts also form the foundation of translational investigation for determination of the right patients. According to this research style, we made ASP3026, an inhibitor of ALK tyrosine kinase. OSI joined Astellas this year, and it is pursuing little molecule drug discovery with a different type using different accuracy medicine methods. Throughout the growth of erlotinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, OSI completed research to better understand which patients optimally take advantage of this treatment and which patients would become refractory or resistant.